Overview
Clinical Meaning
Advanced immunological assessment requires interpretation of serological markers, autoantibody panels, and immunoglobulin levels within clinical context.
PMHNP
PMHNP
Advanced immunological assessment requires interpretation of serological markers, autoantibody panels, and immunoglobulin levels within clinical context. Antinuclear antibody (ANA) testing serves as a screening tool for systemic autoimmune diseases, with specific antibody patterns (anti-dsDNA for SLE, anti-Smith for SLE, anti-Scl-70 for scleroderma, anti-Jo-1 for polymyositis) providing diagnostic specificity. Immunosuppressive pharmacotherapy follows a hierarchy from corticosteroids (rapid anti-inflammatory effect through NF-kB inhibition) to disease-modifying agents (methotrexate inhibiting dihydrofolate reductase, azathioprine inhibiting purine synthesis) to biologics targeting specific cytokines (TNF-alpha inhibitors, IL-6 receptor antagonists). The clinician must balance immunosuppression efficacy against infection risk, monitoring CBC, hepatic function, and screening for latent tuberculosis before initiating biologic therapy.
Unlock full lesson + practice questions
4 more sections with scenarios, priorities, and review drills.
Final rapid review before practice
Next study step
Finish the lesson first, then choose a focused activity to apply what you just reviewed.
Continue studying
Sign in to save progress on this lesson.
Unlock the interactive lesson quiz with a plan that includes this PMHNP pathway. You can still explore topic-filtered questions from the bank hubs below.